$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Detailed description of which diseases and indications Cabergoline is suitable for
2026-02-01 22:25:32
Check Details
Precautions and daily monitoring requirements for taking momelotinib
2026-02-01 22:25:32
Check Details
How long does it take to safely stop taking Bikeren Prenol Tablets (Bituvi) and reference for the medication cycle?
2026-02-01 22:25:32
Check Details
Summary of clinical efficacy and patient use feedback of decavatinib
2026-02-01 22:25:32
Check Details
Analysis of the mechanism and principle of action of Apremilast (Otelor) in the treatment of psoriasis
2026-02-01 22:25:32
Check Details
What blood, liver and kidney indicators need to be checked regularly while using Valganciclovir?
2026-02-01 22:25:32
Check Details
Is osimertinib (Tagrisso) suitable for the treatment of lung squamous cell carcinoma and analysis of its efficacy
2026-02-01 22:25:32
Check Details
Can I eat immediately after taking Eltrombopag (Revlan) and what are my dietary recommendations?
2026-02-01 22:25:32
Check Details
Possible side effects and treatment methods during taking Roprostim (Huierning)
2026-02-01 22:25:32
Check Details
What to do if Midostaurin can cause an allergic skin reaction
2026-02-01 22:25:32
Check Details
Does long-term use of cabergoline cause excessive gastric acid secretion?
2026-02-01 22:25:32
Check Details
Which groups are not suitable for taking Momelotinib and tips on potential risks
2026-02-01 22:25:32
Check Details
1
2
...
2344
2345
2346
2347
2348
2349
2350
...
10229
10230
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Acalabrutinib Dosing and Efficacy Guide: Administration, Response Evaluation, and Safety
2
Osimertinib Treatment and Dosing Guide: Efficacy, Administration, and Precautions
3
Bosutinib Indications Explained: CML Targeted Therapy and ADPKD Research Insights
4
Ceritinib Dosing Guide: 450mg Once Daily with Food – Key Administration Points
5
Ruxolitinib Drug Safety Guide: Drug Interactions, Hepatic/Renal Function, and Infection Risk Management
6
Revumenib Mechanism Explained: Targeting menin-KMT2A Interaction to Reshape Leukemia Cell Fate
7
Pretomanid Combination Therapy Safety Guide: BPaL Regimen Adverse Reaction Recognition and Monitoring
8
Asciminib (Scemblix): Targeted Mechanism, Dosing Regimens, and Missed-Dose Guidance
9
Vigabatrin (Sabril): Mechanism of Action, Pharmacokinetics, and Safety Monitoring
10
Belzutifan (WELIREG) Treatment Guide: Duration, Onset of Action, and Monitoring Protocol
11
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
12
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor